Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.
Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Kuter DJ, et al. Among authors: neale a. N Engl J Med. 2022 Apr 14;386(15):1421-1431. doi: 10.1056/NEJMoa2110297. N Engl J Med. 2022. PMID: 35417637 Clinical Trial.
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study.
Murrell DF, Patsatsi A, Stavropoulos P, Baum S, Zeeli T, Kern JS, Roussaki-Schulze AV, Sinclair R, Bassukas ID, Thomas D, Neale A, Arora P, Caux F, Werth VP, Gourlay SG, Joly P; BELIEVE trial investigators. Murrell DF, et al. Among authors: neale a. Br J Dermatol. 2021 Oct;185(4):745-755. doi: 10.1111/bjd.20431. Epub 2021 Jun 15. Br J Dermatol. 2021. PMID: 33942286 Free PMC article. Clinical Trial.
Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgaris.
Murrell DF, Patsatsi A, Stavropoulos P, Baum S, Zeeli T, Kern JS, Sinclair R, Neale A, Arora P, Sugerman PB, Shi G, Werth VP, Caux F, Joly P; BELIEVE Trial Investigators. Murrell DF, et al. Among authors: neale a. J Eur Acad Dermatol Venereol. 2022 Jun 10. doi: 10.1111/jdv.18318. Online ahead of print. J Eur Acad Dermatol Venereol. 2022. PMID: 35686647 No abstract available.
Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
Hauser RA, Olanow CW, Kieburtz KD, Pourcher E, Docu-Axelerad A, Lew M, Kozyolkin O, Neale A, Resburg C, Meya U, Kenney C, Bandak S. Hauser RA, et al. Among authors: neale a. Lancet Neurol. 2014 Aug;13(8):767-76. doi: 10.1016/S1474-4422(14)70148-6. Epub 2014 Jul 6. Lancet Neurol. 2014. PMID: 25008546 Clinical Trial.
Evaluation of the dopamine β-hydroxylase (DβH) inhibitor nepicastat in participants who meet criteria for cocaine use disorder.
De La Garza R 2nd, Bubar MJ, Carbone CL, Moeller FG, Newton TF, Anastasio NC, Harper TA, Ware DL, Fuller MA, Holstein GJ, Jayroe JB, Bandak SI, Reiman KZ, Neale AC, Pickford LB, Cunningham KA. De La Garza R 2nd, et al. Among authors: neale ac. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jun 3;59:40-48. doi: 10.1016/j.pnpbp.2015.01.009. Epub 2015 Jan 17. Prog Neuropsychopharmacol Biol Psychiatry. 2015. PMID: 25602710 Free PMC article. Clinical Trial.
334 results